Kolexia
Bourcier Kévin Oncologie médicale
Bourcier Kévin
Oncologie médicale
Centre Hospitalier de Pau
Pau, France
55 Activités
16 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sarcomes Métastase tumorale Tumeurs du sein Tumeurs colorectales Tumeurs des voies biliaires Tumeurs du poumon Carcinomes Structures lymphoïdes tertiaires Cholangiocarcinome

Collaborateurs

Voir plus
Italiano Antoine
Italiano Antoine
Institut Bergonié, Bordeaux, France
Toulmonde Maud
Toulmonde Maud
Institut Bergonié, Bordeaux, France
Cousin Sophie
Cousin Sophie
Institut Bergonié, Bordeaux, France
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
MSD
3 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2022
Amgen
2 collaboration(s)
Dernière en 2022
Lilly
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Essai Clinique (Lilly)   29 février 2024
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
TEDOVA: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Essai Clinique (Merck & Co.)   04 décembre 2023
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.
Essai Clinique (Centre Léon-Bérard)   16 novembre 2023
138P Precision medicine phase II study evaluating the efficacy of olaparib in patients with progressive solid cancers and carriers of homologous recombination repair genes alterations
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
InTTercePT: Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression
Essai Clinique (Seagen)   21 septembre 2023
Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten): Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)
Essai Clinique (Centre Léon-Bérard)   31 août 2023
PRISM-POrTAL: Implementing Precision Medicine in cOmmunity HospiTALs
Essai Clinique (Roche)   17 mai 2023
LENVAGIST: A Multicentre, Comparative, Placebo-controlled, Double-blinded, Phase II Study of the Efficacy of Lenvatinib in Patients With Locally Advanced or Metastatic GIST After Failure of Imatinib and Sunitinib
Essai Clinique (Centre Léon-Bérard)   28 mars 2023